Skip to main content
. 2020 Oct 21;2020(10):CD013750. doi: 10.1002/14651858.CD013750

7.3. Analysis.

7.3

Comparison 7: Platinum vs non‐platinum regimens (subgroup analysis 6: homologous recombination deficient status), Outcome 3: Objective tumour response rate (assessable participants)